Inclusion Criteria:  Have hidradenitis suppurativa (HS) for at least 1 year (365 days) prior to the baseline visit as determined by the investigator through participant interview and/or review of the medical history Have Hurley Stage II or Hurley Stage III HS as determined by the investigator at screening and baseline visits Have HS lesions present in at least 2 distinct anatomic areas (examples include but are not limited to left and right axilla; or left axilla and left inguinocrural fold) at screening and baseline visits Have a total abscess and inflammatory nodule (AN) count of greater than or equal to (>=)5 at the screening and baseline visit Agree not to receive a live virus or live bacterial vaccination during the study and for 90 days after the last administration of study intervention  Exclusion Criteria:  Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances Has unstable cardiovascular disease, defined as a recent clinical deterioration (that is, unstable angina, rapid atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months Has or has had herpes zoster within the 2 months before screening Has a transplanted organ (with exception of a corneal transplant greater than [>]3 months before the first administration of study intervention) Has known allergies, hypersensitivity, or intolerance to bermekimab or adalimumab or its excipients